Life Bio Signals Commercial Ambitions with M&A Veteran Webster on Board

BOSTON, MA – August 10, 2026 – In the high-stakes world of biotechnology, board appointments are rarely just about governance; they are strategic signals. Life Biosciences, a company at the vanguard of cellular rejuvenation, sent one of its clearest signals yet by appointing Stephen Webster to its Board of Directors. For a clinical-stage firm that just dosed its first patient and secured a major funding round, bringing on a finance executive renowned for orchestrating multi-billion-dollar acquisitions and landmark IPOs is a definitive statement of intent. This isn't just about adding a seasoned voice; it's about building the financial architecture for a commercial future.

Life Bio is not merely developing another drug. Its entire platform is built on a paradigm-shifting premise: reversing diseases of aging by reprogramming cells to a younger state. With its lead candidate, ER-100, now in Phase 1 trials for debilitating optic neuropathies, the company is moving from theoretical science to clinical reality. The appointment of Webster, a veteran of navigating the treacherous waters from clinical development to market launch and lucrative exit, suggests Life Bio is already planning several moves ahead.

The Architect of Biotech Value

To understand the weight of this appointment, one need only look at Stephen Webster's track record. His career is a blueprint for transforming innovative science into tangible enterprise value. As the former Chief Financial Officer of Spark Therapeutics, he was a central figure in one of modern biotech's most significant success stories. He didn't just manage the books; he architected the financial strategy that fueled the company's ascent.

Webster led approximately $1 billion in equity financings and steered Spark through its 2015 initial public offering. Crucially, he provided the financial stewardship for the commercial launch of LUXTURNA®, the first gene therapy approved in the United States for an inherited disease. Launching a first-in-class, high-value therapy for a rare ophthalmic condition is a complex undertaking, requiring sophisticated financial planning and market strategy. This experience is directly transferable to Life Bio’s ambitions for its own novel eye therapy. His tenure at Spark culminated in its monumental $4.3 billion acquisition by Roche, a deal he helped lead.

“Stephen Webster is an accomplished finance executive and board leader with an exceptional track record,” said Jerry McLaughlin, Chief Executive Officer of Life Bio, in the company’s announcement. “As Life Bio enters its next phase of growth, Stephen’s experience building and scaling innovative biotech companies will be invaluable.”

His Midas touch wasn't limited to Spark. Before that, he served as CFO at both Adolor Corporation and Optimer Pharmaceuticals, guiding both to successful acquisitions by Cubist Pharmaceuticals. This pattern of steering specialized biotechs toward profitable exits makes him one of the industry's most sought-after strategists. His current board roles at companies like Cullinan Therapeutics and NextCure further cement his status as an active and influential figure in biotech governance.

Fortifying the Financial Foundation

For a company like Life Biosciences, Webster’s arrival is perfectly timed. The company is at a critical juncture where capital is the lifeblood of progress. It recently closed a substantial $80 million Series D financing round, securing its operational runway into the second half of 2027. This funding is vital for completing the Phase 1 trial of ER-100, but the journey through Phase 2 and 3 trials will require exponentially more capital.

Webster’s expertise is not just in raising money, but in raising it strategically. "Appointing a finance heavyweight with a history of successful IPOs and M&A sends a powerful signal to investors," noted one industry analyst. "It says the company is serious about financial discipline and is building a board capable of evaluating all strategic options, whether that’s a public offering, a major partnership, or an eventual acquisition."

This move de-risks the company's future in the eyes of the market. It demonstrates a mature understanding that scientific breakthroughs alone don't build a sustainable business. Webster’s presence on the board provides the financial oversight needed to navigate the long and expensive path of clinical development, ensuring that the company’s groundbreaking science is supported by a robust and forward-looking financial strategy.

From Lab Bench to Lifeline

At the heart of Life Bio's mission is its proprietary Epigenetic Restoration platform. The technology uses a specific combination of three transcription factors—OCT4, SOX2, and KLF4 (OSK)—to essentially reset the "software" of aging cells without altering their underlying DNA "hardware." By targeting the epigenetic changes that accumulate over time and contribute to disease, the company aims to restore cells to a functionally younger and healthier state.

Significantly, the platform deliberately omits the c-MYC gene, a factor often used in cellular reprogramming that carries an inherent risk of promoting cancerous growth. This safety-conscious approach was a key element in securing the FDA's clearance to proceed with human trials.

The company's lead program, ER-100, applies this technology to optic neuropathies like open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION)—conditions that cause irreversible blindness through the death of retinal ganglion cells. Current treatments can only slow the progression of glaucoma by managing eye pressure; they cannot repair the damage. For NAION, no approved treatments exist. ER-100 represents a potential leap forward: a therapy designed to reverse cellular damage and restore function.

“I have been impressed with Life Bio’s disciplined and innovative approach to reversing age-related disease,” Mr. Webster stated. “The company has built a compelling scientific foundation and has advanced its technology with a rigorous, data-driven development strategy.”

This sentiment was echoed by company co-founder and board chair, Dr. David Sinclair, a leading figure in aging research. “As we continue to build a leading biotechnology company focused on reversing age-related diseases, his strong financing, industry, and governance experience will be tremendous assets,” Sinclair said of Webster. The combination of Sinclair's scientific vision and Webster's financial and commercial acumen creates a powerful leadership dynamic.

Webster's appointment underscores a critical truth in biotech: translating revolutionary science into medicine requires more than brilliant researchers. It requires leaders who can build the corporate and financial infrastructure to carry that science across the finish line. With a veteran dealmaker and commercial strategist now on board, Life Biosciences has fortified its leadership for the challenging but potentially transformative journey ahead.